A phase 2 clinical trial evaluated the efficacy and safety of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study included 93 patients who received the therapy, with a median follow-up of 14 months. The best overall response rate was 52%, with 40% achieving complete response and 12% partial response. Response rates were consistent across prognostic subgroups. At 12 months, 65% of patients with a complete response remained relapse-free. Common adverse events included cytokine release syndrome (22%), neurologic events (12%), and cytopenias (32%). Three patients died from disease progression within 30 days, but no deaths were attributed to the therapy. Tisagenlecleucel showed durable responses, with some patients maintaining responses for up to 18.4 months. The therapy was well-tolerated, with no significant differences in response based on CD19 expression or immune checkpoint-related proteins. The study demonstrated high response rates and durable remissions, suggesting tisagenlecleucel is a promising treatment for patients with relapsed or refractory DLBCL. The results were supported by a global, multicenter trial with centralized manufacturing and a global supply chain. The study was funded by Novartis and published in the New England Journal of Medicine.A phase 2 clinical trial evaluated the efficacy and safety of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study included 93 patients who received the therapy, with a median follow-up of 14 months. The best overall response rate was 52%, with 40% achieving complete response and 12% partial response. Response rates were consistent across prognostic subgroups. At 12 months, 65% of patients with a complete response remained relapse-free. Common adverse events included cytokine release syndrome (22%), neurologic events (12%), and cytopenias (32%). Three patients died from disease progression within 30 days, but no deaths were attributed to the therapy. Tisagenlecleucel showed durable responses, with some patients maintaining responses for up to 18.4 months. The therapy was well-tolerated, with no significant differences in response based on CD19 expression or immune checkpoint-related proteins. The study demonstrated high response rates and durable remissions, suggesting tisagenlecleucel is a promising treatment for patients with relapsed or refractory DLBCL. The results were supported by a global, multicenter trial with centralized manufacturing and a global supply chain. The study was funded by Novartis and published in the New England Journal of Medicine.